

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/644,588-Conf. #5265
				Filing Date	August 20, 2003
				First Named Inventor	Connie Sanchez
				Art Unit	1614
				Examiner Name	A. A. Lewis
Sheet	1	of	1	Attorney Docket Number	05432/100M919-US3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
7EB	CA	Schoffers, E. et al., Enantioselective syntheses through enzymatic asymmetrization. Tetrahedron, 52, 3769-3826, 1996.		
7EB	CB	Feighner, JP et al., The Journal of Clinical Psychiatry, 60, 824-830, 1999.		
7EB	CC	Ulla M. Lepola et al., "Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care", <i>International Clinical Psychopharmacology</i> (2003) Vol. 18, No. 4, pp. 211-217		
7EB	CD	Ulla Lepola et al., "Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder", <i>International Clinical Psychopharmacology</i> 2004, Vol 19, No. 3, pp.149-156.		
7EB	CE	James L. Schaller et al., "Treating Comorbid ADHD, Major Depression, and Panic", J. Neuropsychiatry and Clinical Neuroscience, 11:4, Fall 1994, pp. 516.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/12/07
-----------------------	---	--------------------	---------